NCT05517317 (ABMNCBA) is a Phase 1 clinical trial of Autologous BMMC transplantation in Biliary Atresia, sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

Who is sponsoring NCT05517317?

NCT05517317 is sponsored by Vinmec Research Institute of Stem Cell and Gene Technology.

What drugs are being tested in NCT05517317?

Interventions in NCT05517317: Autologous BMMC transplantation.

What condition does NCT05517317 study?

NCT05517317 studies Biliary Atresia.

Is NCT05517317 still recruiting?

NCT05517317 is currently completed. Last updated 26 August 2022.

Last reviewed 2022-08-26 · How we verify

NCT05517317: ABMNCBA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous BMNC Infusion for Liver Cirrhosis in Children With BA

Completed Phase 1 Last updated 26 August 2022

What this trial tests

Phase 1 trial testing Autologous BMMC transplantation in Biliary Atresia in 12 participants. Completed in 30 May 2022.

Timeline

1 January 2015

Primary endpoint
30 May 2022

30 May 2022

Quick facts

Lead sponsor	Vinmec Research Institute of Stem Cell and Gene Technology
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 January 2015
Primary completion	30 May 2022
Estimated completion	30 May 2022
Sites	1 location across Vietnam

Drugs / interventions tested

Autologous BMMC transplantation

Conditions studied

Biliary Atresia — all drugs for Biliary Atresia →

Sponsor

Vinmec Research Institute of Stem Cell and Gene Technology

Who can join

Adults 2 Months to 15, any sex, with Biliary Atresia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and early outcomes of autologous bone marrow mononuclear cell (BMMNC) infusion for liver cirrhosis due to biliary atresia (BA) after Kasai operation. An open-label clinical trial was performed from January 2015 to December 2021. 12 children with liver cirrhosis due to BA at the time of Kasai or after Kasai were included. Bone marrow was harvested through anterior iliac crest puncture under general anesthesia. Mononuclear cells (MNCs) were isolated by Ficoll gradient centrifugation and then infused into the hepatic artery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.
Zhao J, Yue P, Mi N, Li M, et al · · 2024 · cited 5× · PMID 39135601 · DOI 10.1515/mr-2024-0029
Modified Kasai operation combined with autologous bone marrow mononuclear cell infusion for biliary atresia.
Thanh LN, Nguyen HP, Kieu TPT, Duy MN, et al · · 2024 · cited 3× · PMID 39568009 · DOI 10.1186/s12893-024-02669-9
Magnetic Nanostructures and Stem Cells for Regenerative Medicine, Application in Liver Diseases.
Barreto da Silva T, Dias EA, Cardoso LMDF, Gama JFG, et al · · 2023 · cited 1× · PMID 37298243 · DOI 10.3390/ijms24119293
Modified Kasai operation combined with autologous bone marrow mononuclear cell infusion for biliary atresia
Nguyen T, Nguyen H-P, Phan TKT, Ngo DM, et al · · 2023 · DOI 10.21203/rs.3.rs-3357053/v1

Verify or expand the search:

Other trials of Autologous BMMC transplantation

Trials testing the same drug.

NCT03468699 — Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia · Phase 2 · completed

Other recruiting trials for Biliary Atresia

Currently open trials in the same condition.

NCT06764082 — Nutritional Intervention for Biliary Atresia · NA · recruiting
NCT06564740 — Stem Cell Applications in Biliary Atresia Patients · NA · recruiting
NCT05925309 — Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy · NA · recruiting
NCT05072626 — High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia · recruiting
NCT04272515 — Molecular Characterization for Understanding Biliary Atresia · NA · recruiting

Other Vinmec Research Institute of Stem Cell and Gene Technology trials

Trials by the same sponsor.

NCT07472270 — Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment · Phase 1 · not yet recruiting
NCT06629324 — Evaluating Bone Marrow Cell Transplant for Treating Cerebral Palsy From Brain Hypoxia · Phase 2 · recruiting
NCT06726538 — Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Func · Phase 1, PHASE2 · completed
NCT06027957 — CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia · Phase 1 · completed
NCT05329662 — Adipose Tissue-derived Mesenchymal Stem Cell (AD-MSC) Therapy for the Treatment of Sexual Function Impairment in Female · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05517317 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vinmec Research Institute of Stem Cell and Gene Technology
Last refreshed: 26 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05517317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing